Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly receives NICE recommendation for Alimta

Lilly receives NICE recommendation for Alimta

6th April 2010

Lilly has received a recommendation from the National Institute for Health and Clinical Excellence (NICE) for Alimta, a chemotherapy treatment for lung cancer patients.

The organisation granted Lilly’s treatment a Final Appraisal Determination based on data showing that it can improve overall survival rates for advanced nonsquamous non-small cell lung cancer (NSCLC) sufferers.

This recommendation improves the chances that Alimta will now be approved for NHS funding, having already received European Commission approval in July 2009.

NICE will issue its final guidance on the drug in summer 2010.

John Johnson, president of Lilly Oncology, said: “This decision is a promising step toward recognising the value of Alimta for patients, payer organisations and doctors it means more advanced nonsquamous NSCLC patients may have access to treatment.”

Last week, Lilly announced it is extending its clinical trial materials supply chain relationship with Thermo Fisher Scientific in order to improve the efficiency of its development programmes.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.